Department of Pathology and Lab Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.
Curr Osteoporos Rep. 2011 Dec;9(4):258-63. doi: 10.1007/s11914-011-0080-1.
This review examines the use of platelet-rich plasma (PRP) in the treatment of bone injuries and to stimulate bone formation. Studies examining both in vivo bone healing and in vitro actions of PRP on osteoblasts are reviewed. Overall, the available literature suggests that PRP does not appreciably impact bone healing or induce bone formation. However, there is some evidence to suggest that PRP might augment recruitment of osteoblast progenitors to injection sites or in sites expected to experience delayed healing. In this capacity PRP might be utilized to initiate repair of an otherwise poorly healing skeletal lesion. The demonstration that PRP is a viable therapy is hindered by a lack of standardized criteria for what constitutes PRP, and more studies are needed to compare the efficacy of PRP to that of transforming growth factor-β or platelet-derived growth factor used as sole agents.
这篇综述考察了富血小板血浆(PRP)在治疗骨损伤和刺激骨形成中的应用。综述了研究 PRP 对成骨细胞的体内骨愈合和体外作用的研究。总的来说,现有文献表明 PRP 不会显著影响骨愈合或诱导骨形成。然而,有一些证据表明 PRP 可能会增加成骨细胞祖细胞向注射部位或预计愈合延迟的部位的募集。在这种情况下,PRP 可用于启动对原本愈合不良的骨骼病变的修复。由于缺乏构成 PRP 的标准化标准,PRP 作为一种可行的治疗方法的证明受到阻碍,需要更多的研究来比较 PRP 与作为单一药物的转化生长因子-β或血小板衍生生长因子的疗效。